FDA panel votes against MDMA for PTSD, setting up hurdle to approval

[ad_1]

FDA advisers cited a variety of concerns with the trials submitted by Lykos Therapeutics as part of the application.

[ad_2]

, 2024-06-04 23:53:33

Source link

Related posts

Mayor Mamdani Unveils Vision Zero Reimagined to Make Streets Safer for Every New Yorker

NYC Unveils $5B Housing Plan

Who Will Replace Joey Chestnut?

This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Read More